
IMMUTEP Ltd
IMMUTEP Ltd (IMMP)
WebsitePrice
Market cap
Next catalystDec 14, 2026Eftilagimod alfa + pembrolizumab — TACTI-003, including CPS <1 Cohort B · Phase 2 dataCompany source ↗
Cash
Chart & Events
Core Clinical
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
PreINDP1P2P3FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
History / paused
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Financial position
Upcoming milestones
Financial history
Annual trends
| Reported item | |||||
|---|---|---|---|---|---|
Reported shares and borrowings
Ownership and institutions
| Status | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|